In the present study, bufalin inhibits TGF-β-triggered EMT and the consequent cell migration of lung cancer A549 cells by downregulation of the TGF-β receptors, thus, providing novel evidence for its anticancer effect. This evidence concerns the gene TGFB1 and lung cancer.